Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw. 2022 Jul;20(7):815-833. doi: 10.6004/jnccn.2022.0035.

Abstract

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.

Publication types

  • Practice Guideline

MeSH terms

  • Extremities / pathology
  • Humans
  • Medical Oncology
  • Sarcoma* / drug therapy
  • Sarcoma* / therapy
  • Soft Tissue Neoplasms* / diagnosis
  • Soft Tissue Neoplasms* / pathology
  • Soft Tissue Neoplasms* / therapy